1. Home
  2. PERI vs ADCT Comparison

PERI vs ADCT Comparison

Compare PERI & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Perion Network Ltd.

PERI

Perion Network Ltd.

HOLD

Current Price

$10.46

Market Cap

422.4M

Sector

Technology

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$3.46

Market Cap

445.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PERI
ADCT
Founded
1999
2011
Country
Israel
Switzerland
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
422.4M
445.2M
IPO Year
2005
2019

Fundamental Metrics

Financial Performance
Metric
PERI
ADCT
Price
$10.46
$3.46
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$14.50
$7.75
AVG Volume (30 Days)
232.3K
1.2M
Earning Date
05-20-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
30.86
EPS
N/A
N/A
Revenue
N/A
$81,357,000.00
Revenue This Year
$9.98
N/A
Revenue Next Year
$2.48
$66.49
P/E Ratio
N/A
N/A
Revenue Growth
N/A
14.85
52 Week Low
$8.07
$1.69
52 Week High
$11.44
$4.98

Technical Indicators

Market Signals
Indicator
PERI
ADCT
Relative Strength Index (RSI) 51.83 35.18
Support Level $9.37 $3.40
Resistance Level $10.54 $3.59
Average True Range (ATR) 0.33 0.22
MACD -0.05 -0.04
Stochastic Oscillator 33.47 12.34

Price Performance

Historical Comparison
PERI
ADCT

About PERI Perion Network Ltd.

Perion Network Ltd is a technology company. It offers online advertising and search solutions to brands, agencies, and publishers through desktop, mobile, and social channels. It connects advertisers to consumers across digital advertising channels, including search advertising, social, display, video, digital audio, digital out of home (DOOH), and Connected TV (CTV) advertising. The company earns prime revenue from search advertising and display advertising services. It operates in the business segment of High Impact Advertising solutions. Geographically, the company generates a majority of its revenue from the United States and the rest from other regions.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: